Insmed Incorporated (INSM)
39.79 +0.04 (0.09%)
After hours: 4:11PM EST
Chart Events
Performance Outlook
| Previous Close | 39.18 |
| Open | 39.83 |
| Bid | 39.73 x 1000 |
| Ask | 42.40 x 800 |
| Day's Range | 38.92 - 40.58 |
| 52 Week Range | 12.09 - 40.71 |
| Volume | 610,558 |
| Avg. Volume | 848,969 |
| Market Cap | 4.049B |
| Beta (5Y Monthly) | 2.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | Feb 23, 2021 - Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.22 |
- PR Newswire
Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:00 a.m. ET.
- PR Newswire
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFBE). Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of NCFBE and other inflammatory diseases.
- PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
